Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
Fu De Yang,1 Juan Li,1 Yun Long Tan,1 Wei Ye Liang,1 Rongzhen Zhang,1 Ning Wang,1 Wei Feng,1 Shangli Cai,2 Jian Min Zhuo,2 Li Li Zhang2 1Beijing Hui-Long-Guan Hospital, 2Department of Medical Affairs, Xian Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China Objective: The aim...
Saved in:
Main Authors: | Yang FD, Li J, Tan YL, Liang WY, Zhang R, Wang N, Feng W, Cai S, Zhuo JM, Zhang LL |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/4be20db0d4234dc9ab21b5594bf58fd8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
by: Jariyavilas A, et al.
Published: (2017) -
Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
by: Zhang LL, et al.
Published: (2016) -
Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
by: Si T, et al.
Published: (2019) -
Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
by: Zhao JP, et al.
Published: (2017) -
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
by: Mathews M, et al.
Published: (2020)